FDA — authorised 21 December 2023
- Application: NDA217388
- Marketing authorisation holder: ASTRAZENECA AB
- Local brand name: WAINUA
- Indication: SOLUTION — SUBCUTANEOUS
- Status: approved
🇺🇸 Wainua in United States
FDA authorised Wainua on 21 December 2023
Marketing authorisations
FDA
- Marketing authorisation holder: ASTRAZENECA AB
- Status: approved
Wainua in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Neuroscience approved in United States
Frequently asked questions
Is Wainua approved in United States?
Yes. FDA authorised it on 21 December 2023; FDA has authorised it.
Who is the marketing authorisation holder for Wainua in United States?
ASTRAZENECA AB holds the US marketing authorisation.